🇺🇸 FDA
Patent

US 8198255

SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1

granted A61KA61K31/7105A61K9/127

Quick answer

US patent 8198255 (SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1) held by The Board of Regents of the University of Oklahoma expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/7105, A61K9/127, A61K9/19